Rotator-cuff / subacromial pain: mixed or unspecified subtype · Review · 2014
When does a Dutch guideline suggest shockwave for shoulder pain?
This Dutch guideline from 2014 says high-energy shockwave can be considered when calcium deposits in the shoulder tendons are confirmed. Needle rinsing of the deposit is the other option it lists. It advises against shockwave in the acute phase or when there are no calcium deposits.
- year the guideline was published
- 2014
- options it lists for calcium deposits
- 2
- clinical questions covered
- 8
Good to know: This is guideline advice, not a trial; it gives no shockwave dose or measured results.
Diercks R, Bron C, Dorrestijn O, et al. Acta Orthopaedica, 2014 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
What the trials used
- ESWT indication and protocol detail
- The guideline says high-energy ESWT can be considered for confirmed subacromial calcium deposits and is not recommended in the acute phase or without calcific tendinosis/bursitis. Device, focused/radial type, energy, pulses, sessions and comparator are not specified.
Who took part
Not a trial: a multidisciplinary Dutch guideline for people with subacromial shoulder pain, including those with calcium deposits.
Side effects
The guideline does not report side effects of shockwave.
All the numbers and the full appraisal
Every reported result
What the full paper reports.
Multidisciplinary Dutch guideline/review addressing subacromial pain syndrome (SAPS), including calcific tendinosis as a distinct subgroup; not a trial cohort.
High-energy ESWT for calcific tendinosis1 reported outcome
High-energy ESWT for calcific tendinosis
No numeric outcome estimate in guideline
The guideline states ESWT or ultrasound-guided needling/barbotage can be used for calcific tendinosis. Its Level 1 evidence conclusion, citing one systematic review (Huisstede et al. 2011), is that high-energy ESWT reduces pain and improves shoulder function more than low-energy ESWT or placebo in calcific tendinosis. It gives no numeric effect; citing Diehl et al. 2011, it finds no obvious preference among ESWT, barbotage and surgical removal, and advises against surgery because equivalent alternatives exist.
Analysis details and source
This is a guideline recommendation resting on a Level 1 conclusion from the cited review (the working group used consensus only where evidence was lacking), not a treatment trial result. The underlying ESWT studies were not independently reread for this extraction.
ESWT for acute or non-calcific SAPS1 reported outcome
ESWT for acute or non-calcific SAPS
Recommendation; no numeric estimate
The guideline advises against ESWT in the acute phase and when calcific tendinosis/bursitis is absent. Its Level 1 conclusion (Huisstede et al. 2011) is that ESWT of any form is no more effective than placebo or other treatments for pain or shoulder function without calcium deposits.
Analysis details and source
The recommendation is diagnosis-specific and should not be generalized to calcific disease. No independent primary-trial estimate is provided here.
How treatment was delivered
The guideline says high-energy ESWT can be considered for confirmed subacromial calcium deposits and is not recommended in the acute phase or without calcific tendinosis/bursitis. Device, focused/radial type, energy, pulses, sessions and comparator are not specified.
This guideline section does not provide comparative adverse-event counts or systematic ESWT harm monitoring.
The authors describe heterogeneity in populations, factors, follow-up and outcome measures, with some uncertainty distinguishing SAPS from broader shoulder/neck pain.
The document is a 2014 guideline review; it provides no ESWT-specific trial outcome table, dose specification, or comparative effect estimate. Current applicability depends on later evidence not covered here.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- The authors describe heterogeneity in populations, factors, follow-up and outcome measures, with some uncertainty distinguishing SAPS from broader shoulder/neck pain.
- The document is a 2014 guideline review; it provides no ESWT-specific trial outcome table, dose specification, or comparative effect estimate. Current applicability depends on later evidence not covered here.
Source-linked critical reading
Clinical guideline supported by an evidence review
Technical source record
Complete HTML text read, all three raw tables and ESWT recommendation passages cross-checked; underlying primary trials unavailable.
This older guideline suggests shockwave only for confirmed shoulder calcium deposits, not for acute or non-calcific subacromial pain. It gives no numeric benefit estimate or protocol.
What diagnostic and treatment guidance does the Dutch multidisciplinary group offer for subacromial pain syndrome, including calcific tendinosis?
Multidisciplinary guideline/review by the Dutch Orthopaedic Association; eight clinical questions; exploratory searches and evidence-level synthesis.
People with subacromial pain syndrome; recommendations distinguish acute/chronic symptoms, rotator-cuff disorders and calcific tendinosis. This is not a treatment trial.
High-energy ESWT may be considered for confirmed calcific deposits. Device, focus/radial type, energy, shocks and sessions are not specified.
The guideline discusses exercise, injections, ultrasound-guided barbotage, imaging, rehabilitation and surgery; it does not provide a direct ESWT comparator trial in the extracted recommendation.
No numeric ESWT pain/function outcome, follow-up or comparative estimate is supplied. The recommendation is that ESWT or barbotage may be used for calcific tendinosis.
No numeric estimate is given. Citing Diehl et al. 2011, the guideline finds no obvious preference among ESWT, barbotage and surgical removal for calcific tendinosis. The guideline's Level 1 conclusion, from one cited systematic review, is that high-energy ESWT beats low-energy ESWT or placebo in calcific tendinosis, while ESWT is no better than placebo or other treatments without calcium deposits. The guideline advises against ESWT in acute SAPS and when calcification is absent.
No systematic ESWT adverse-event data or comparison is given.
Evidence synthesis reports heterogeneous populations, outcome measures and follow-up; SAPS definitions overlap with general shoulder/neck pain. Document dates from 2014; underlying evidence was not rechecked.
Apply only to the specific calcific subgroup and interpret as older guideline advice, not a current dose recommendation or quantified benefit.
Updated comparative reviews and trials should report confirmed diagnosis, calcification status, ESWT type/dose, comparator, patient-important outcomes and harms.
Read the original article.
Guideline for diagnosis and treatment of subacromial pain syndrome: a multidisciplinary review by the Dutch Orthopaedic Association.
Diercks R, Bron C, Dorrestijn O, Meskers C, Naber R, de Ruiter T, Willems J, Winters J, van der Woude HJ, Dutch Orthopaedic Association. · Acta orthopaedica · 2014
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →